TransEnterix (TRXC) Tops Q3 EPS by 1c

TransEnterix (NYSE: TRXC) reported Q3 EPS of ($0.06), $0.01 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $5.27 million.

• Total revenue of $5.4 million, including the sale of four Senhance™ Systems in the third quarter
• Acquired the technology assets and IP of MST Medical Surgery Technologies
• Received FDA 510(k) clearance for 3mm diameter instruments
• Received CE Mark approval for Senhance™ Ultrasonic Instrument System

“We are proud of the progress we made during the third quarter, as we continued to drive adoption of the Senhance System by executing on our sales and marketing strategy and continuing to develop the capabilities of the Senhance System to deliver on our vision of digital laparoscopy,” said Todd M. Pope, President and CEO at TransEnterix. “We are focused on driving the global adoption of the Senhance System by increasing the applicability of the system for a wider range of surgeons, patients and geographies.”

For earnings history and earnings-related data on TransEnterix (TRXC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79